Bridge to Life supplies organ preservation products and organ perfusion technologies.
Founded in 2005 and based in Duluth, US, Bridge to Life provides organ preservation solutions in collaboration with surgeons and transplant professionals. In August 2026, it raised USD 110 million in Series C and venture debt funding from Soleus Capital and Lauxera Capital Partners. The funding is intended to support the US rollout of its VitaSmart HOPE System and further product development.
3 rounds recorded · latest Private placement (Form D), Aug 2026
Sign in to see 3 rounds.
Sign inSign in to see 3 investors.
Sign inSign in to see 2 more people.
Sign inBridge to Life Ltd. has no recorded acquisitions.
Add an acquisitionStill private — no exit on record.
Record an exitNo diversity signals recorded yet for Bridge to Life Ltd..
Add diversity data